Benzinga | Oct 26, 2021 07:12AM EDT

RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $34

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Outperform and raises the price target from $23 to $34.